摘要辅助生殖技术(ART)过程中由于黄体功能不全(LPD),需要常规进行黄体支持(LPS).近年来研究表明促性腺激素释放激素激动剂(GnRH-a)能有效应用于LPS,改善ART结局.目前有关其应用范围、最小有效剂量、给药时机以及用药方案尚未达成共识,有效作用机制尚不明确,可能与刺激黄体,直接作用于胚胎以及子宫内膜等存在GnRH-a受体相关.GnRH-a用于LPS仍需要大样本、多中心研究,在不断探究其有效性过程中进一步明确其适用范围、作用机制及安全性,适时正确合理用药.

abstractsAs a clinical routine,luteal phase support (LPS) is recommended in assisted reproductive technique (ART) cycles due to luteal insufficiency (LPD).Administration of gonadotropin-releasing hormone agonist (GnRH-a) has been recently suggested as an alternative for LPS on ART to improve clinical outcomes in recent years.The exact underlying mechanism is still not clear,although it has been hypothesized that GnRH-a either supports the corpus luteum function or stimulates the GnRH-a receptors on the endometrium and embryo.It is necessary to further explore the formulation of GnRH-a,the scope,the minimal effective dosage,the most effective timing,protocol and safety,as well as its exact mechanism.